myeloma

Latest Posts

First and solely subcutaneous anti-CD38 remedy demonstrating potential to stop end-organ harm, and prolong...

Market

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) exhibits 51 % discount in threat of development to energetic a number of myeloma for sufferers with high-risk...

SAN DIEGO - Poseida Therapeutics, Inc. (NASDAQ:PSTX), a biopharmaceutical firm, introduced new interim medical...

Market

Poseida stories excessive response in a number of myeloma trial By Investing.com